The effect of levosimendan on the prognosis of patients with acute myocardial infarction treated with emergency PCI during perioperation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900020994

Enrollment

Unknown

Registered

2019-01-24

Start date

2019-02-15

Completion date

Unknown

Last updated

2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular disease

Interventions

Group 1:levosimendan

Group 2:conventional therapy

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Diagnostic criteria of STEMI and non-STEMI: Chest pain lasting for >30 min that was not relieved by treatment with sublingual nitroglycerin, ST-segment elevation = 2 mm in at least two electrocardiographic leads and increases in serum troponin and creatine kinase-MB (CK-MB) to levels at least twice their upper limits of normal, new left bundle branch block.

Exclusion criteria

Exclusion criteria: 1. right coronary occlusion or acute inferior-posterior myocardial infarction; 2. cardiac shock or mechanic complication; 3. major surgery,injury,hemorrhagic disease,acute cerebrovascular disease; 4. intolerability of antiplatelet drugs; 5. liver and kidney insufficiency; 6. contraindications for levosimendan; 7. not suitable for emergency PCI treatment: Pregnancy, malignant Tumor.

Design outcomes

Primary

Measure	Time frame
heart function;myocardial infarction area;inflammatory factors;30 days MACE;	—

Countries

China

Contacts

Public ContactWang Zhengzhong

Qingdao Municipal Hospital

wangzhengzhong0523@163.com+86 18661675619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026